Hyperphosphatemia in end stage renal disease patients undergoing maintenance hemodialysis at a tertiary care hospital in Ras Al Khaimah, UAE

Syed Arman Rabbani1, Sathvik B S 1, Padma G M Rao1, Martin Thomas2 and A B El Essawy2
1 RAK Medical and Health Sciences University, UAE
2 Ibrahim bin Hamad Obaidallah Hospital, UAE

The objective of the study was to assess the prevalence of hyperphosphatemia in End Stage Renal Disease patients (ESRD) undergoing maintenance hemodialysis at a tertiary care hospital in Ras Al Khaimah, UAE. The study also aimed to describe the characteristics of the ESRD patients with hyperphosphatemia. The study was a prospective, observational study including all the patients undergoing hemodialysis at the nephrology unit of the hospital. Patients who were on hemodialysis for less than six months, with less than thrice weekly hemodialysis and with acute kidney injury were excluded from the study. Patient’s characteristics were compared according to phosphatemia level, between patients with or without hyperphosphatemia of the 80 patients included (mean age, 61.1 ± 9.4 years), 73.8% had hyperphosphatemia, defined by a mean serum phosphate > 1.45 mmol/L. Patients with hyperphosphatemia are younger and have a higher BMI than those with normal phosphate levels, and more often women. They were more likely to have hypertensive and diabetic nephropathy, and had less comorbidity. The study showed that ESRD patients with hyperphosphatemia differ from those with normal phosphate levels.

Biography
Syed Arman Rabbani has completed his PhD in Clinical Pharmacology from the Clinical Pharmacology Unit, Ranbaxy Research Laboratories in collaboration with Jamia Hamdard University, New Delhi, India. He is a University Gold Medalist. Currently, he is working as an Assistant Professor in Department of Clinical Pharmacy and Pharmacology, RAK College of Pharmaceutical Sciences, RAK Medical and Health Sciences University. He has a rich blend of experience in both industry as well as academics. In industry, he was involved in the conceptualization and conduct of Phase III and Phase IV Clinical Trials.

Notes: